Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adultsClinical Trial Published on 2023-03-102023-07-11 Journal: Vaccine [Category] COVID19(2023년), [키워드] clinical trial COVID-19 vaccine immunogenicity preclinical study Recombinant spike protein Safety. [DOI] 10.1016/j.vaccine.2022.12.025 PMC 바로가기 [Article Type] Clinical Trial
Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trialArticle Published on 2022-11-012022-11-15 Journal: Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% confidence interval Administered adverse event approved assessment booster booster dose booster vaccination clinical trials Course COVID-19 COVID-19 vaccination COVID-19 vaccine cross-neutralization cross-neutralization. Day double-blind Effect fatigue Heterologous homologous humoral immunogenic immunogenicity incidence injection site pain Local Neutralizing antibodies neutralizing antibody outcome participant Participants Placebo placebo-controlled primary immunogenicity Randomized randomized placebo-controlled trial Recombinant spike protein reported robust Safe Safety safety profile saline placebo SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variants Serious Adverse Event Serious Adverse Events Seroconversion seroconversion rate shown SpikoGen subunit the placebo group Trial Vaccine was performed [DOI] 10.1111/imm.13540 PMC 바로가기
Systematic analysis and comparison of O-glycosylation of five recombinant spike proteins in β-coronavirusesArticle Published on 2022-10-162022-11-15 Journal: Analytica chimica acta [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] acute respiratory syndrome Analysis antiviral drug Biological functions cell entry characterization characterized Coronavirus-2 D614G domains FIVE functional glycosylated help less membrane fusion mutant N-glycosylation O-glycosylation Recombinant spike protein S proteins S1 protein S1 subunit SARS-CoV-2 Sialylation spike Spike protein Spike proteins Vaccine β-coronavirus β-coronavirus β-coronavirus. β-CoV β-CoVs [DOI] 10.1016/j.aca.2022.340394 PMC 바로가기
Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2Article Published on 2022-09-292022-11-15 Journal: Vaccine [Category] SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome analyzed B.1.1.529 binding binding antibodies binding antibody breakthrough Breakthrough infection calibrated coronavirus correlated include individual Infection longitudinal cohort study marker Neutralizing activity Neutralizing antibodies neutralizing antibody occurred omicron Permissive Population ranged Recombinant spike protein S1 domain SARS-CoV-2 SARS-CoV-2. sequence sera Spike protein the spike protein vaccination rates variant WHO World Health Organization Wuhan-Hu-1 [DOI] 10.1016/j.vaccine.2022.08.058 PMC 바로가기
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trialClinical Trial Published on 2022-08-102022-10-06 Journal: The Lancet. Infectious Diseases [Category] SARS, 변종, 진단, [키워드] 1:1 Administered administration adverse event adverse events age amplifying analysed Analysis antibody concentration Antigen assigned available data BMI booster booster dose Breastfeeding Coalition Contraception COVID-19 pandemic diagnosis of COVID-19 dose Efficacy enrolled evaluated event Evidence exclusion geometric mean titre GMT group healthy homologous IgG immune response inactive increase in initial intramuscular Local Matrix-M median Medical conditions Novavax NVX-CoV2373 outcome participant per-protocol per-protocol population phase 2 trial phase 3 study Placebo placebo-controlled pregnant primary endpoint proportion Protein randomisation randomised Randomly reaction reactogenicity receive Recombinant spike protein recruited regimens Registered Safety SARS-CoV SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 vaccine SARS-CoV-2 variant screened serum IgG single booster dose stratified Support the SARS-CoV-2 the vaccine titres Treatment Trial USA vaccination Vaccine variant were excluded women [DOI] 10.1016/S1473-3099(22)00420-0 PMC 바로가기 [Article Type] Clinical Trial
Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study일본 참가자의 S-268019-b 또는 BNT162b2 추가 용량의 면역원성과 안전성: 2/3상, 무작위, 관찰자 맹검, 비열등성 연구의 중간 보고서Clinical Trial Published on 2022-07-302022-09-11 Journal: Vaccine [Category] MERS, 변종, 임상, 진단, [키워드] 95% CI analyzed Anti-spike antibodies BNT162b2 booster booster dose Booster vaccine clinical clinical trial co-primary endpoint co-primary endpoints COVID-19 Delta elicited fatigue Fever geometric mean geometric mean titer GMT GMT ratio immunization immunogenicity Immunoglobulin Immunoglobulin G injection Injection-site pain Interim report Interim result interim results Japanese Live virus MOST myalgia neutralization test Neutralizing antibodies neutralizing antibody observer observer-blinded omicron P-value participant phase 2/3 produced pseudovirus Randomized reactogenicity recombinant Recombinant spike protein regimen reported robust Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2. Serious Adverse Event Serious Adverse Events Spike protein subgroups T-cell Response Vaccine variant [DOI] 10.1016/j.vaccine.2022.06.032 PMC 바로가기 [Article Type] Clinical Trial
Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern구조 선택 RBM 면역원은 우려되는 SARS-CoV-2 변이체를 중화하는 다클론성 기억 반응을 일으킵니다.Article Published on 2022-07-212022-09-11 Journal: PLoS Pathogens [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 Affect Amino acid amino acid residue antibody Antibody Response B.1.351 B.1.617.2 booster C57BL/6 can be used conserved COVID-19 pandemic domain effort full-length full-length spike protein immunization immunogen immunogenic immunogens Immunoglobulin majority memory response mice neutralize Neutralizing Neutralizing antibodies neutralizing antibody Plasmid polyclonal Prevent Protein Proteins purified RBD RBM receptor-binding motif Recombinant spike protein resulting SARS-CoV-2 variant sera spike Spike protein Spike proteins the antibody response Transmission Vaccine variants variants of concern virus VoC VOCs vulnerability WA1 wildtype [DOI] 10.1371/journal.ppat.1010686 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trialHIV-1 감염 여부에 관계없이 살고 있는 사람들을 대상으로 한 SARS-CoV-2 재조합 스파이크 단백질 나노입자 백신의 면역원성과 안전성: 무작위, 대조, 2A/2B상 시험Clinical Trial Published on 2022-05-012022-09-12 Journal: The Lancet. HIV [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 1:1 amplification angiotensin-converting enzyme 2 anti-Spike IgG antibody Antiretroviral therapy article assigned baseline clinical Coalition Cohort COVID-19 COVID-19 vaccine death dosage Efficacy and safety ELISA endpoints enrolled enrolment evaluated first vaccination geometric mean titre GMT GMTs HIV-1 HIV-1 viral HIV-negative humoral immune response immunogenicity increased risk individual injection interim analysis intervention group Intramuscular injection less Local Matrix-M Melinda Gate multicentre neutralising antibody titres Novavax NVX-CoV2373 NVX-CoV2373 vaccine observer-blinded occurred PACTR202009726132275 participant Participants paucity of data Placebo placebo-controlled provided randomised Randomly reactive receive Recombinant spike protein Registered registry remained reported safety analysis SARS-CoV-2 SARS-CoV-2 nucleic acid SCR SCRs second vaccination Serious Adverse Event Serious Adverse Events seroconversion rate serostatus South Africa stratified study group Support systemic adverse event the placebo group the vaccine Trial vaccination Vaccine vaccine immunogenicity Volume was used were assessed [DOI] 10.1016/S2352-3018(22)00041-8 PMC 바로가기 [Article Type] Clinical Trial
An adjuvanted subunit SARS-CoV-2 spike protein vaccine provides protection against Covid-19 infection and transmission Research Published on 2022-02-232022-10-05 Journal: NPJ Vaccines [Category] 변종, 임상, 치료기술, [키워드] Administered anti-spike antibody approach B.1.617.2 characterized Complete COVID-19 vaccine D614G effective elicited hamsters humoral induce Infection intramuscularly mice monomeric naïve neutralizing antibody offer prevented provide provided RBD Recombinant protein Recombinant spike protein Safe SARS-COV-2 infection SARS-CoV-2 spike protein spike receptor-binding domain subunit T-cell Response Transmission Vaccine variants Viral transmission wild-type [DOI] 10.1038/s41541-022-00450-8 [Article Type] Research
Escherichia coli recombinant expression of SARS-CoV-2 protein fragmentsResearch Published on 2022-02-052022-10-29 Journal: Microbial Cell Factories [Category] COVID-19, COVID19(2023년), MERS, SARS, [키워드] Escherichia coli affinity tag Amino acid antibody antigenic antigenic protein approach C-terminal Carbohydrate-binding module CBM9 conserved COVID-19 Degradation E. coli epitope Escherichia coli expressed expression expression of SARS-CoV-2 flexible fusion protein human convalescent sera linker N-terminal overlapping protease Proteases Protective Protein purified Receptor binding domain Recombinant spike protein regions SARS-CoV-2 SARS-CoV-2 protein shown Spike protein supplementary material tested the SARS-CoV-2 [DOI] 10.1186/s12934-022-01753-0 PMC 바로가기 [Article Type] Research